Skip to contentE
Ernexa Therapeutics Inc.
E
ERNAWErnexa Therapeutics Inc. ERNAW Q4 2011 · Ernexa Therapeutics Inc. · ThalerReleased Mar 29, 2012, after the close
10-K filed Mar 30, 2012, 90 days after period end · 0001019687-12-001146
Q4 2011 · 10-K
Revenue$6.10M$6.10Mno prior Q4 2010 on file+4.0% vs Q3 2011 Net Income-$1.04M-$1.04M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR
N/M vs Q3 2011
EPS Diluted-$0.02-$0.02no prior Q4 2010 on fileN/M vs Q3 2011 Operating Income-$908,000— Operating Cash Flowderived-$127,000N/M Free Cash Flowderived-$419,000N/M Margins · derivedOperating margin-14.9%
Net margin-17.0%
ended Dec 31, 2011 · filed Mar 30, 2012 · 90 d after period end